Imara Raises $50M In Equity Funding To Support Development Of Sickle Cell Treatment Candidate

  • Imara Inc IMRA has priced its previously announced underwritten public offering of shares at $6.00 per share for gross proceeds of $50 million.
  • The offering will close by July 16.
  • Underwriters have an option to purchase up to $7.5 million of additional shares.
  • Morgan Stanley, SVB Leerink, and Cantor are acting as joint book-running managers for the offering.
  • Proceeds will be used to advance IMR-687 for sickle cell disease and beta-thalassemia and working capital and other general corporate purposes.
  • In June, IMR-687 data was presented at the EHA Congress, wherein final data from the 93-patient Phase 2a trial showed a lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687.
  • In March, data monitoring committees endorsed the opening of higher dose IMR-687 treatment arms in ongoing Phase 2b trials after reviewing safety and tolerability data at lower doses.
  • See the offering prospectus here.
  • Price Action: IMRA shares closed at $7.09 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFinancingOfferingsGeneralBriefsSickle Cell Disease
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!